MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
1:32 PM | Tuesday | Jul 21, 2026 Fool - Investing News

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

NEW News Thumbnail
6:51 PM | Monday | Jul 20, 2026 Zacks Investment Research

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

News Thumbnail
6:10 PM | Monday | Jul 20, 2026 The Motley Fool

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.

News Thumbnail
6:51 PM | Monday | Jul 20, 2026 Zacks Investment Research

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

News Thumbnail
6:10 PM | Monday | Jul 20, 2026 The Motley Fool

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.

News Thumbnail
12:01 PM | Friday | Jul 17, 2026 Zacks Investment Research

MRNA Advances Cancer Pipeline With New Immunotherapy Study

News Thumbnail
7:00 AM | Thursday | Jul 16, 2026 Accesswire

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

News Thumbnail
1:37 PM | Tuesday | Jul 14, 2026 Proactive Investors

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

News Thumbnail
9:35 AM | Tuesday | Jul 14, 2026 Proactive Investors - Finance

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

News Thumbnail
8:00 AM | Monday | Jul 13, 2026 Seeking Alpha

Arbutus Biopharma: Moderna Validates My IP Bull Case

News Thumbnail
12:04 PM | Friday | Jul 10, 2026 24/7 Wall Street

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

News Thumbnail
7:17 AM | Thursday | Jul 9, 2026 Reuters

Moderna wins EU contract for RSV vaccine supply

News Thumbnail
7:00 AM | Thursday | Jul 9, 2026 Accesswire

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

News Thumbnail

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

Fool - Investing News

1:32 PM | Tuesday | Jul 21, 2026

news photo
Loading...

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

Read full article redirect
1:32 PM | Tuesday | Jul 21, 2026

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

Fool - Investing News

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

Read full article arrow
NEW News Thumbnail
6:51 PM | Monday | Jul 20, 2026

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Investment Research

In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.

Read full article arrow
News Thumbnail
6:10 PM | Monday | Jul 20, 2026

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.

The Motley Fool

Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials.

Read full article arrow
News Thumbnail
6:51 PM | Monday | Jul 20, 2026

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Investment Research

In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.

Read full article arrow
News Thumbnail
6:10 PM | Monday | Jul 20, 2026

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.

The Motley Fool

Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials.

Read full article arrow
News Thumbnail
12:01 PM | Friday | Jul 17, 2026

MRNA Advances Cancer Pipeline With New Immunotherapy Study

Zacks Investment Research

Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jul 16, 2026

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.

Read full article arrow
News Thumbnail
1:37 PM | Tuesday | Jul 14, 2026

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

Proactive Investors

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.

Read full article arrow
News Thumbnail
9:35 AM | Tuesday | Jul 14, 2026

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

Proactive Investors - Finance

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...

Read full article arrow
News Thumbnail
8:00 AM | Monday | Jul 13, 2026

Arbutus Biopharma: Moderna Validates My IP Bull Case

Seeking Alpha

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.

Read full article arrow
News Thumbnail
12:04 PM | Friday | Jul 10, 2026

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

24/7 Wall Street

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

Read full article arrow
News Thumbnail
7:17 AM | Thursday | Jul 9, 2026

Moderna wins EU contract for RSV vaccine supply

Reuters

Moderna said on Thursday it has secured a European Commission contract to ​supply its respiratory syncytial virus vaccine ‌to six countries in the region.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jul 9, 2026

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

Read full article arrow
News Thumbnail